-
Longitude Prize on ALS Announces Judge Panel
Bio-IT World | Last month, the Longitude Prize on ALS announced the judgement panel for the prize. The panel consists of leaders and experts from neuroscience, technology, and pharmaceutical fields from around the world.
Oct 21, 2025
-
uniQure’s Huntington’s Disease Trial Shows Promising Results
Bio-IT World | Last month, uniQure announced promising results from their Phase I/II study of AMT-130, the company’s gene therapy to treat Huntington’s disease. A participant pool of 29 patients in the early stages of Huntington’s disease was categorized into two groups—low-dose and high-dose—and compared to a control group of 1,600 untreated Huntington’s patients at similar disease stages.
Oct 16, 2025
-
New Immunotherapy Approach Hits the Sweet Spot with Solid Tumors
Bio-IT World | Glycans, the complex sugar chains found at abnormally high levels on the surface of cancer cells, have historically been difficult to target effectively with traditional antibody therapies. One of the biggest reasons is that T cells can’t present glycans to B cells so they can make antibodies that bind strongly and stably to the target antigen.
Oct 15, 2025
-
TOR Inhibitors Could One Day Be Multi-Purpose Healthspan Drugs
Bio-IT World | The Target of Rapamycin (TOR) signaling pathway is a prime target for therapeutic development, since its dysregulation is implicated in promoting aging and a range of age-related diseases. By inhibiting TOR, the prescription medication rapamycin has been successfully used to prevent organ transplant rejection and treat certain cancers, but its use for anti-aging purposes in healthy individuals has yet to be approved by the Food and Drug Administration (FDA).
Oct 14, 2025


